Drug intelligence / Profile preview

hydrochlorothiazide + losartan

Development stage
Phase 4
Lead developer
Caplet India
Modality
Small Molecules
Administration
Oral
01

Overview

Lotak H Tablet is a fixed-dose combination antihypertensive medication containing the angiotensin II receptor blocker (ARB) losartan potassium (50 mg) and the thiazide diuretic hydrochlorothiazide (12.5 mg). Developed and marketed by Caplet India, it is indicated for the management of hypertension (high blood pressure) in patients whose blood pressure is not adequately controlled by monotherapy. Losartan works by selectively blocking the binding of angiotensin II to the AT1 receptor, thereby promoting vasodilation and reducing peripheral vascular resistance. Hydrochlorothiazide acts on the distal convoluted tubule of the kidney to inhibit sodium and chloride reabsorption, promoting diuresis and natriuresis to reduce blood volume. Together, these two active ingredients work synergistically to lower blood pressure and reduce the risk of cardiovascular events such as stroke and myocardial infarction.

Brand names
Lotak HLotak H 50mg/12.5mg TabletLotak H Tablet
Other names
hydrochlorothiazide + losartan potassiumlosartan + hydrochlorothiazidelosartan potassium + hydrochlorothiazide
02

Targets

AGTR1 (Angiotensin II Type-1 receptor)SLC12A3 (Thiazide-sensitive sodium-chloride cotransporter)

Beyond the preview

Go deeper on hydrochlorothiazide + losartan.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on hydrochlorothiazide + losartan.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call